Cancer stem cells (CSCs) are thought to be the core reason behind tumor clonal evolution [106], and thus widely believed to be the driving force behind tumor progression [107]. Cells with CSC characteristics have been isolated from OC cell lines [108,109]. EMT is also thought to relate t...
AEs and clinical laboratory tests were evaluated throughout treatment per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v5.0. Tumor response was evaluated by radiological imaging per RECIST 1.1 and irRECIST, at baseline and every 6 weeks until progression,...
To investigate the role of lncRNA LINC00665 in modulating ovarian cancer stemness and its influence on treatment resistance and cancer development. We isolated ovarian cancer stem cells (OCSCs) from the COC1 cell line using a combination of chemotherapeu
experienced grade 3–5 AEs, including treatment-related mortality. While lenvatinib has received regulatory approval for various solid tumors (including thyroid cancer, hepatocellular carcinoma, and renal cell cancer) with recommended starting doses ranging from 8 mg to 24 mg, anti-tumor activity has ...
The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe....
cancer stem cells and targeted therapy Vahideh Keyvani1,2, Moein Farshchian3, Seyed-Alireza Esmaeili4,5, Hadi Yari6, Meysam Moghbeli2, Seyed-Reza Kazemi Nezhad2* and Mohammad Reza Abbaszadegan1* Abstract Background: Ovarian cancer has the highest ratio of mortality among gynecologic ...
During an international workshop held in September 1998, a group of specialists in the field of ovarian cancer reached consensus on a number of issues with implications for standard practice and for research of advanced epithelial ovarian cancer. Methods Five groups of experts considered several issue...
Olaparib is a relatively new poly(ADP-ribose) polymerase inhibitor (PARPi) administered to ovarian cancer (OC) patients with a complete or partial response to first-line chemotherapy. One of the metabolic side effects of olaparib is the disruption of glucose homeostasis, often resulting in hypergly...
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to assess activit
The Drug Development Unit is supported by Cancer Research UK through a programme grant to the Section of Medicine, Institute of Cancer Research, and through an Experimental Cancer Medical Centre (ECMC) grant (C51/A7401). It is also supported by the Department of Health through the ECMC grant ...